Results 211 to 218 of about 118,712 (218)

Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors

New England Journal of Medicine, 1998
exaly  

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

Lancet, The, 2013
exaly  

Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load

Lancet, The, 1997
exaly  

Inhibitors of HIV-1 reverse transcriptase.

Advances in pharmacology (San Diego, Calif.), 2001
M A, Parniak, N, Sluis-Cremer
openaire   +1 more source

HIV Non-Nucleoside Reverse Transcriptase Inhibitors

2007
openaire   +1 more source

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial

Lancet, The, 2006
exaly  

HIV-1-specific Reverse Transcriptase Inhibitors

1995
openaire   +1 more source

ANTIGEN TEST VERSUS REVERSE TRANSCRIPTASE ASSAY FOR DETECTING HIV

Lancet, The, 1987
exaly